Key Takeaways
- The Government of Canada is providing $80 million over four years to support Phase 2 of the Marathon of Hope Cancer Centres Network.
- The network plans to add 11,000 cancer cases and expand genomic data systems to support precision oncology research and treatment.
- The Terry Fox Research Institute and participating institutions will match the federal investment, creating a potential $160 million combined funding commitment.
Canada Invests $80 Million in Precision Cancer Research to Personalize Treatment
The Government of Canada is investing $80 million over four years to support precision oncology research through the Terry Fox Research Institute (TFRI), with the goal of expanding personalized cancer care and strengthening research capacity across the country.
The investment supports Phase 2 of the Marathon of Hope Cancer Centres Network, a national initiative focused on using genomic and biological information to help inform cancer treatment.
What Is Precision Oncology?
Precision oncology uses information about the genetic and biological characteristics of cancer cells to help doctors and researchers understand which treatments may be more appropriate for individual patients.
The approach can help researchers study why some patients respond differently to cancer treatments and support the development of more personalized treatment strategies.
$80 Million Investment Will Expand Cancer Research Network
The federal government committed $80 million over four years, beginning in the 2026-27 fiscal year, to support the next phase of the Marathon of Hope Cancer Centres Network.
The TFRI and participating institutions will match the Government of Canada's $80 million investment. Together, the funding could unlock a total of $160 million for precision oncology research through the network.
The investment builds on work carried out by the network over the past six years to establish a national strategy for precision oncology research.
Network Plans to Add 11,000 Cancer Cases
Under Phase 2, the network plans to add 11,000 new cancer cases to its data resources while strengthening the systems needed to generate, analyze and return genomic results that can inform patient care.
The network has already developed a data repository containing genome sequences from cancerous tumours involving more than 16,000 patients.
Researchers can use this information to study differences in treatment responses and investigate approaches that could contribute to improved cancer care.
Expansion to More Canadian Institutions
The next phase will also expand participation across Canada, including the onboarding of additional cancer institutions from the territories.
The TFRI is also working to provide genetic testing for family members when a patient is identified as having a type of cancer that can be inherited.
The expansion is intended to strengthen collaboration between researchers, clinicians and healthcare institutions while supporting access to advanced cancer care across jurisdictions.
Focus on Equitable Access to Personalized Cancer Care
The Government of Canada says the investment will support real-time clinical genomic data generation, workforce capacity and broader access to precision oncology.
The initiative is designed to strengthen Canada's national cancer research infrastructure while helping translate genomic research into information that can be used in clinical care.
The announcement also builds on Canada's broader efforts to accelerate cancer research and improve cancer prevention, diagnosis and treatment.
What Happens Next?
Phase 2 of the Marathon of Hope Cancer Centres Network will focus on expanding its data resources, bringing additional institutions into the network and strengthening systems for genomic testing and analysis.
The federal investment, combined with matching contributions from the TFRI and participating institutions, is expected to support continued development of Canada's precision oncology research capacity.
The Government of Canada says the work will contribute to a national approach to precision cancer research and personalized care.